company background image
2349 logo

Jinghua Pharmaceutical Group SZSE:002349 Stock Report

Last Price

CN¥7.71

Market Cap

CN¥6.3b

7D

4.2%

1Y

-28.3%

Updated

25 Apr, 2024

Data

Company Financials

Jinghua Pharmaceutical Group Co., Ltd.

SZSE:002349 Stock Report

Market Cap: CN¥6.3b

2349 Stock Overview

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China.

2349 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends4/6

Jinghua Pharmaceutical Group Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jinghua Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥7.71
52 Week HighCN¥11.00
52 Week LowCN¥5.88
Beta0.11
1 Month Change-2.90%
3 Month Change-0.52%
1 Year Change-28.28%
3 Year Change63.35%
5 Year Change16.47%
Change since IPO129.92%

Recent News & Updates

Recent updates

Shareholder Returns

2349CN PharmaceuticalsCN Market
7D4.2%0.8%-0.4%
1Y-28.3%-13.4%-14.4%

Return vs Industry: 002349 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.

Return vs Market: 002349 underperformed the CN Market which returned -14.4% over the past year.

Price Volatility

Is 2349's price volatile compared to industry and market?
2349 volatility
2349 Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement7.7%
Market Average Movement8.8%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 002349 has not had significant price volatility in the past 3 months.

Volatility Over Time: 002349's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19571,641Yunzhong Zhouwww.jinghuapharm.com

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd.

Jinghua Pharmaceutical Group Co., Ltd. Fundamentals Summary

How do Jinghua Pharmaceutical Group's earnings and revenue compare to its market cap?
2349 fundamental statistics
Market capCN¥6.28b
Earnings (TTM)CN¥247.70m
Revenue (TTM)CN¥1.51b

25.3x

P/E Ratio

4.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2349 income statement (TTM)
RevenueCN¥1.51b
Cost of RevenueCN¥775.64m
Gross ProfitCN¥736.11m
Other ExpensesCN¥488.41m
EarningsCN¥247.70m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)0.30
Gross Margin48.69%
Net Profit Margin16.38%
Debt/Equity Ratio0.8%

How did 2349 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

27%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.